BMX-001 is under clinical development by Biomimetix JV and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect BMX-001’s likelihood of approval (LoA) and phase transition for High-Grade Glioma took place on 22 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BMX-001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
BMX-001 overview
BMX-001 is under development for the treatment of allergic dermatitis, anal squamous cell carcinoma, rectal adenocarcinoma (RAC), high-grade gliomas, reperfusion injury, squamous cell carcinoma of head and neck cancer including oropharyngeal cancer, laryngeal cancer, hypopharyngeal cancer, oral cavity cancer and metastatic brain tumor. It is administered by subcutaneous and topical route. BMX-001 is a Mn(III) N-substituted pyridylporphyrin (MnP)-based SOD mimic.
Biomimetix JV overview
Biomimetix JV (Biomimetix) develops a new class of redox active metalloporphyrin compounds for the treatment of inflammatory skin disease and cancer patients undergoing radiation therapy and chemotherapy. Its pipeline products include BMX-001 targeting high-grade glioma, head and neck cancers, brain metastases, and anal cancer and BMX-010 indicated for the treatment of atopic dermatitis, pruritus (itch), acne, psoriasis, rosacea, and other chronic inflammatory skin conditions. Biomimetix’s compounds modulates key nuclear transcription factors to inhibit inflammatory pathways and also stimulating the production of antioxidants. Biomimetix is headquartered in Greenwood Village, Colorado, the US.
Quick View BMX-001 LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|